PODCAST: Drugs, magazines, and bonds

The FDA is expected to take another look at controversial diabetes drug Avandia after researchers at Duke have concluded the drug doesn't increase the risk of cardiovascular death as previously reported. - Joe Raedle/Getty Images

The FDA is expected to take another look at controversial diabetes drug Avandia after researchers at Duke have concluded the drug doesn't increase the risk of cardiovascular death as previously reported. But is it too little too late?

Shelter magazines are on the rebound as the housing industry bounces back. What other lateral signs are there out there?

Stocks are risky, but bonds are safe, or so goes the stereotype. Buy a solid bond -- the logic goes -- and you get your money back at maturity with interest. Then there are bond mutual funds, which are built on bonds, but are a very different animal than straight up bonds. As interest rates have risen over the past month, dividends for some of the nation's largest bond funds have been all but wiped out.

David Brancaccio is the host of American Public Media’s Marketplace Morning Report, now a regular segment on NPR’s Morning Edition. His reporting focuses on the future of the economy, financial and labor markets, technology, the environment and social enterprises.